Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Autor:
Maria Kościuszko, Angelika Buczyńska, Katarzyna Łuka, Ewa Duraj, Katarzyna Żuk-Czerniawska, Agnieszka Adamska, Katarzyna Siewko, Aleksandra Wiatr, Adam Jacek Krętowski, Anna Popławska-Kita
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Oxidative stress (OS) plays a pivotal role in the pathogenesis of insulin resistance (IR), particularly in its association with obesity. This study evaluate both the diagnostic and clinical significance of assessing oxidative status in patients affec
Externí odkaz:
https://doaj.org/article/6f3ced44c364495e89c4f08e819ec1aa
Autor:
Kyungha Min, Bumjo Oh, Hye Yeon Koo, Yang-Hyun Kim, Ji-Won Lee, Sangsub Lee, Youngah Kim, Hyuktae Kwon
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Glaceum Inc. has proposed HSG4112, a structural analogue of glabridin, as a novel anti-obesity compound. Animal studies and phase I human trials have shown that HSG4112 improves energy consumption, normalises weight, and is safe and drug-
Externí odkaz:
https://doaj.org/article/88d4e45a96b844b19819f5ef6b404e96
Autor:
Yu-Ning Liao, Hsing-Yu Chen, Ching-Wei Yang, Pai-Wei Lee, Chiu-Yi Hsu, Yu-Tung Huang, Tsung-Hsien Yang
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/d7f51bf4f8c14dcc8a5ed08db5f712f1
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: The prevalence of obesity is increasing worldwide, causing a global health issue. Traditional Chinese medicine (TCM) used in treating overweight/obesity has been widely implemented in clinical practice, but its overall efficacy and safety
Externí odkaz:
https://doaj.org/article/16cca0fd4c734314a69a534a33ecec9b
Autor:
Yu-Ning Liao, Hsing-Yu Chen, Ching-Wei Yang, Pai-Wei Lee, Chiu-Yi Hsu, Yu-Tung Huang, Tsung-Hsien Yang
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Introduction: In Taiwan, many people receive Chinese herbal medicine (CHM) as an alternative choice to help control body weight. However, the clinical effectiveness of CHM on weight control has not been well studied, while potential risks and adverse
Externí odkaz:
https://doaj.org/article/8f39c0e3009242848bf01287a1765aa1
Autor:
Teresa Giani, Salvatore De Masi, Ilaria Maccora, Francesca Tirelli, Gabriele Simonini, Martina Falconi, Rolando Cimaz
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Background: There is evidence that obesity could be a risk factor for the severity and response to treatment in adult patients with rheumatoid arthritis (RA) due both to the mechanical effect of overweight and to the potential pro-inflammatory effect
Externí odkaz:
https://doaj.org/article/d1cca235cafc46f4a0dde16853db61b1
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2018)
Externí odkaz:
https://doaj.org/article/d141b56634da4a4ea9bd3bf84c9cf1c2